CA2726817A1 - Identification et utilisation de marqueurs pronostiques et predictifs dans le traitement du cancer - Google Patents

Identification et utilisation de marqueurs pronostiques et predictifs dans le traitement du cancer Download PDF

Info

Publication number
CA2726817A1
CA2726817A1 CA2726817A CA2726817A CA2726817A1 CA 2726817 A1 CA2726817 A1 CA 2726817A1 CA 2726817 A CA2726817 A CA 2726817A CA 2726817 A CA2726817 A CA 2726817A CA 2726817 A1 CA2726817 A1 CA 2726817A1
Authority
CA
Canada
Prior art keywords
chrl
chr2
chrl2
chr5
chrl7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2726817A
Other languages
English (en)
Inventor
Soonmyung Paik
Chungyeul Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NSABP Foundation Inc
Original Assignee
NSABP Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NSABP Foundation Inc filed Critical NSABP Foundation Inc
Publication of CA2726817A1 publication Critical patent/CA2726817A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6841In situ hybridisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2726817A 2008-06-02 2009-06-02 Identification et utilisation de marqueurs pronostiques et predictifs dans le traitement du cancer Abandoned CA2726817A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13067808P 2008-06-02 2008-06-02
US61/130,678 2008-06-02
PCT/US2009/003382 WO2009148593A1 (fr) 2008-06-02 2009-06-02 Identification et utilisation de marqueurs pronostiques et prédictifs dans le traitement du cancer

Publications (1)

Publication Number Publication Date
CA2726817A1 true CA2726817A1 (fr) 2009-12-10

Family

ID=41398399

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2726817A Abandoned CA2726817A1 (fr) 2008-06-02 2009-06-02 Identification et utilisation de marqueurs pronostiques et predictifs dans le traitement du cancer

Country Status (6)

Country Link
US (1) US20090304697A1 (fr)
EP (1) EP2304053A1 (fr)
KR (1) KR20110018930A (fr)
AU (1) AU2009255599A1 (fr)
CA (1) CA2726817A1 (fr)
WO (1) WO2009148593A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
WO2009144690A1 (fr) * 2008-04-14 2009-12-03 Royal College Of Surgeons In Ireland Procédé d’évaluation de l’état d’un cancer chez un patient atteint d’un cancer du sein
GB201000688D0 (en) * 2010-01-15 2010-03-03 Diagenic Asa Product and method
WO2012023286A1 (fr) * 2010-08-19 2012-02-23 Oncotherapy Science, Inc. Lrrc42 comme gène cible pour le traitement et le diagnostic du cancer
CN103492566B (zh) * 2011-04-25 2017-06-13 东丽株式会社 乳癌患者对曲妥珠单抗的治疗敏感性预测用组合物和方法
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
US10648035B2 (en) 2012-11-26 2020-05-12 The Johns Hopkins University Methods and compositions for diagnosing and treating gastric cancer
WO2014130617A1 (fr) * 2013-02-22 2014-08-28 Genomic Health, Inc. Procédé de prédiction d'un pronostic de cancer du sein
CN103913576B (zh) * 2013-05-07 2016-03-16 上海良润生物医药科技有限公司 Cystatin SN 和CA15-3在制备诊断和预示乳腺癌标志物中的应用
EP3134549A4 (fr) * 2014-04-21 2017-11-22 Mayo Foundation for Medical Education and Research Matériels et méthodes pour identifier et traiter des mammifères ayant un cancer du sein her2-positif
CN114870017A (zh) * 2022-05-07 2022-08-09 温州医科大学附属第六医院 Tmem100在调控肺癌5-氟尿嘧啶耐药的应用
CN115992217B (zh) * 2022-09-30 2023-09-22 中国人民解放军总医院第二医学中心 用于诊断乳腺癌化疗导致的心肌损伤的环状rna标志物、试剂盒及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065940A2 (fr) * 2004-12-15 2006-06-22 Nsabp Foundation, Inc. Identification et utilisation de marqueurs pronostiques et predictifs dans le traitement du cancer

Also Published As

Publication number Publication date
US20090304697A1 (en) 2009-12-10
KR20110018930A (ko) 2011-02-24
WO2009148593A1 (fr) 2009-12-10
AU2009255599A1 (en) 2009-12-10
EP2304053A1 (fr) 2011-04-06

Similar Documents

Publication Publication Date Title
CA2726817A1 (fr) Identification et utilisation de marqueurs pronostiques et predictifs dans le traitement du cancer
US9066963B2 (en) Methods of treating breast cancer with anthracycline therapy
US20090203051A1 (en) Targets in breast cancer for prognosis or therapy
US20190134004A1 (en) Methods and compositions for treating breast and prostate cancer
US20140364439A1 (en) Markers associated with chronic lymphocytic leukemia prognosis and progression
US20200140953A1 (en) Methods for diagnosing, prognosing, and treating colorectal cancer using biomarker expression
US20160017438A1 (en) Methods of treating breast cancer with taxane therapy
WO2014058317A1 (fr) Procédés et moyens de prédiction de résistance à un traitement anti-cancer
JP2018532992A (ja) 個別化薬物治療計画の開発方法、及びプロテオミックプロファイルに基づく標的薬物開発
EP3044332A1 (fr) Procédés et kits de prévision de résultat et procédés et kits pour le traitement du cancer du sein par radiothérapie
Martens-de Kemp et al. The FA/BRCA pathway identified as the major predictor of cisplatin response in head and neck cancer by functional genomics
Li et al. Overexpression of LACTB, a mitochondrial protein that inhibits proliferation and invasion in glioma cells
Currais et al. Colorectal cancer carcinogenesis: From bench to bedside
WO2022053065A1 (fr) Biomarqueur utilisé pour prédire ou évaluer des patients atteints d'un cancer du poumon, procédé de détection et application
US20160317601A1 (en) Methods and compositions related to hsp90 inhibitors and breast cancer
EP3980561A1 (fr) Compositions et méthodes de traitement des carcinomes pulmonaires, colorectaux et mammaires
US20090130096A1 (en) Gene Signature of Early Hypoxia to Predict Patient Survival
US20090035311A1 (en) Identification and use of prognostic and predictive markers in cancer treatment
Takeshita et al. Transcriptomic and functional pathway features were associated with survival after pathological complete response to neoadjuvant chemotherapy in breast cancer
US20200325544A1 (en) Methods for diagnosis, prognosis and treatment of primary and metastatic basal-like breast cancer and other cancer types
Zou et al. LncRNA MIR210HG promotes the proliferation, migration, and invasion of lung cancer cells by inhibiting the transcription of SH3GL3
Frick et al. CpG promoter hypo-methylation and up-regulation of microRNA-190b in hormone receptor-positive breast cancer
D'Agostino et al. Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer
Dwivedi et al. Precision medicine in ovarian carcinoma
Guo Detection of somatic mutations and copy number alterations in circulating tumour DNA in patients with primary breast cancer by next-generation sequencing: an in-depth analysis of the Neocent trial to evaluate the efficacy of neoadjuvant therapy

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130604